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INTRODUCTION
Cystic fibrosis (CF) is caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR; AB-
CC7) gene located on the long arm of chromosome 7 (1). The
gene product of CFTR forms an anion selective ion channel
which is required for the normal function of epithelia lining
the airways, intestinal tract, pancreatic duct, and vas deferens.
Clinical features of CF include an exocrine pancreatic insuf-
ficiency and male infertility; however the major cause of mor-
bidity and mortality is caused by pulmonary diseases (2). 
In addition to the presence of typical clinical features, the
diagnosis of CF is assisted by several other findings, such as
a history of CF in a sibling, positive sweat Cl- test, identifi-
cation of CFTR mutations, and an abnormal nasal potential
difference (4). CF is the most common life-threatening genetic
disease of Caucasians and its incidence in Europe is approxi-
mately 1 in 1,000-3,000 newborns (5). CF is rare in the Kore-
an population. Thus far only a few cases have been reported
(6-9). Here, we report a Korean CF patient who was diag-
nosed by both typical clinical features and a positive sweat
chloride test. The genetic analysis of patient’s CFTR gene
and the related molecular functional study revealed that the
patient had a pathogenic L441P mutation in one allele.
CASE REPORT
A 5-yr-old girl was admitted to Sanggye Paik Hospital
due to chronic productive cough and greenish sputum. Eight
months prior to the current hospitalization, she developed
cough, sputum, rhinorrhea, and fever which were associated
with frequent respiratory tract infection. 
She was born by vaginal delivery. A meconium staining of
the amniotic fluid was observed at delivery, but the evidence
of meconium aspiration was not clear. Her birth weight was
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The L441P Mutation of Cystic Fibrosis Transmembrane conductance
Regulator and its Molecular Pathogenic Mechanisms in a Korean
Patient with Cystic Fibrosis 
Cystic fibrosis (CF) is an autosomal recessive disorder usually found in populations
of white Caucasian descent. CF is caused by mutations in the Cystic Fibrosis Trans-
membrane conductance Regulator (CFTR) gene. A 5-yr-old Korean girl was admit-
ted complaining of coughing and greenish sputum. Chest radiographs and comput-
ed tomographic (CT) scan revealed diffuse bronchiectasis in both lungs. The patient
had chronic diarrhea and poor weight gain, and the abdominal pancreaticobiliary
CT scan revealed atrophy of the pancreas. Finally, CF was confirmed by the repeat-
ed analysis of the quantitative pilocarpine iontophoresis test. The chloride concen-
tration of sweat samples taken from both forearms of the pateint was an average
of 88.7 mM/L (normal value <40 mM/L). After a comprehensive search for mutations
in the CFTR gene, the patient was found to carry the non-synonymous L441P muta-
tion in one allele. Molecular physiologic analysis of the L441P mutation of CFTR
revealed that the L441P mutation completely abolished the CFTR Cl- channel activ-
ity by disrupting proper protein folding and membrane trafficking of CFTR protein.
These results confirmed the pathogenicity of the L441P mutation of CFTR circulat-
ing in the Korean population. The possibility of CF should be suspected in patients
with chronic bronchiectasis, although the frequency of CF is relatively rare in East
Asia.
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2.45 kg, which was small for her gestational age (40 week).
She had an older brother while the CF in family history or
CF-related symptoms were found negative from her older
brother. The patient had been suffered from diarrhea persist-
ed from 3 months of age, which led to hospitalization and
poor weight gain since then. She had been hospitalized for
three times from 2 yr of age due to recurrent pneumonia and
respiratory problems. Her body weight and height on admis-
sion were 12.2 kg (<3 percentile) and 95.9 cm (10-25 per-
centile), respectively.
Chest radiographs and computed tomographic (CT) scans
showed bilateral diffuse bronchial wall thickening and sym-
metric bronchiectasis in both lung fields (Fig. 1). The dis-
eases caused by immunodeficiency or allergic reactions were
ruled out by her normal complete blood cell count, serum
immunoglobulin levels and specific IgE levels. P. aeruginosa
was cultured from her sputum. Abdominal ultransound and
pancreaticobiliary CT scan revealed moderate to severe fatty
liver and atrophy of the pancreas. Because she had chronic
diarrhea, poor weigh gain, and atrophy of the pancreas as
well as pulmonary symptoms, the patient was suspected to
have CF.
To confirm the diagnosis, the sweat chloride concentration
was measured by a quantitative pilocarpine iontophoresis
sweat test recommended by the National Committee for
Clinical Laboratory Standards, USA (National Committee
for Clinical Laboratory Standards. Sweat Testing: Sample
Collection and Quantitative Analysis. Villnova, Pa: Nation-
al Committee for Clinical Laboratory Standards; 1997 NC-
CLS document C34-A.). The test was repeatedly performed
at Yongdong Severance Hospital, Yonsei University on two
separate days. The average sweat chloride concentrations on
both forearms were 78.3 mM/L and 99.0 mM/L in two sep-
arate measurements with a one-week interval. These values
were over the reference limit (<40 mM/L) and highly sug-
gestive of CF.
An initial genetic screening was performed on the 11 mu-
tation/polymorphism loci of CFTR gene previously identi-
fied in the Korean population (10) and on the 10 most com-
mon disease-associated loci in Caucasians using the SNaP
Shot method (Applied Biosystems, Foster City, CA, USA).
However, none of the above mutations were identified in the
patient’s gene. Therefore, we next scanned the genetic varia-
tions in the CFTR gene using the denaturing gradient gel
electrophoresis (DGGE) and subsequent nucleotide sequenc-
ings to find unknown CFTR mutations as previously detailed
(10). Interestingly, a non-synonymous L441P mutation of
CFTR was identified in one allele by DGGE and consecu-
tive nucleotide sequencings (Fig. 2). Although we performed
a comprehensive search for the entire coding regions and exon-
intron splicing junctions of CFTR gene, no additional muta-
tions were found. Among family members, patient’s mother
was available for genetic tests. However, no CFTR mutations
including L441P were found in the blood samples from pati-
ent’s mother (Fig. 2). Therefore, the L441P mutation was
assumed to come from patient’s father. 
It has been reported that the L441P mutation of CFTR is
associated with CF in Japan and its allele frequency was esti-
mated around 4.5% among CF patients in Japan (5). How-
ever, the molecular pathogenic mechanisms of the L441P
mutation of CFTR are currently unknown. Therefore, we
investigated the disease-causing mechanism of L441P using
Fig. 1. Chest radiographs on admission. (A) Chest plain radiograph shows diffuse reticulonodular densities in both central lung areas sym-
metrically. (B) On computed tomographic image with lung window setting, diffuse bronchiectasis is seen in both lungs. There are hyper-
lucent areas in the lung parenchyma due to peripheral bronchial obstruction.
A B
168 H.Y. Gee, C.K. Kim, S.W. Kim, et al.
A B
Patient
A
WT
Band C
Lysate
Blot: 
anti-CFTR Ab (M3A7)
L441P WT
Mother
Exon 9 (Ex9.2)
L441P
250
CTG  → CCG: L441PPatient
Forward Reverse
T/C A/G
T A
Forward Reverse
Mother
Fig. 2. Denaturing gradient gel electrophoresis (DGGE) and nucleotide sequencing. (A) DGGE on CFTR exon 9 using the DNA sample
from patient shows a typical heterozygote banding pattern containing heteroduplex bands (see reference no. 10). (B) Nucleotide sequenc-
ing shows that the patient’s CFTR gene contains a mutation changed from T nucleotide at 1454 to C (heterozygous for L441P, CTG:Leu
→ CCG; Pro).
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Fig. 3. Immunoblotting and surface biotinylation of L441P mutant CFTR protein. HEK 293 cells were transfected with plasmids for wild type
CFTR or CFTR carrying the L441P mutation and protein samples were blotted with anti-CFTR M3A7 antibody (Cell Signaling Technology,
Danvers, MA). (A) Most of the wild type CFTR protein was detected as the fully glycosylated mature form (band C), whereas virtually all of
the L441P mutant protein appeared as the core-glycosylated form of around 150 kDa (band B). Surface proteins were collected using
the avidin-biotin interaction. Surface proteins were labeled with EZ-Link biotin-LC-Hydrazide (Pierce, Rockford, IL) and the biotinylated
proteins were pelleted with the UltraLink Immobilized NeutrAvidin beads (10%, Pierce). (B) The ER-localized protein calnexin was not
detected in the biotinlyated fractions, and demonstrating that biotin conjugates were specifically from the cell-surface proteins.
an integrated molecular and physiologic study. The CFTR
plasmid carrying a L441P mutation was constructed by site-
directed mutagenesis using QuickChange kit (Stratagene,
La Jolla, CA, USA) with pCMV-CFTR plasmid according
to the manufacturer’s protocol. The residue thymine base at
1454 of CFTR was substituted with cytosine and the muta-
genic sequence was confirmed by the DNA sequencing. The
total amount of CFTR protein was compared in HEK 293
cells transfected with plasmids for wild type CFTR or CFTR
carrying the L441P mutation by immunoblotting of total
cell lysates. In addition, the amount of surface-expressed pro-
teins was examined by the immunoblotting of surface bio-
tinylated proteins. 
During secretory pathway, the polypeptidic chain of CFTR
undergoes post-translational modifications at its glycan moi-
ety in the Golgi complex to produce the fully glycosylated
mature form, also known as band C, of about 170-180 kDa
(11). In immunoblotting of cell lysates, most of the wild type
CFTR protein was detected as the fully glycosylated mature
form, whereas virtually all of L441P mutant proteins appe-
ared as the ER core-glycosylated form of about 150 kDa, also
known as band B (Fig. 3). These results imply that the L441P
mutant CFTR protein has a defect in the ER-to-Golgi traf-
ficking of the secretory pathway of membrane protein. Con-
sequently, the surface biotinylation results revealed that the
L441P mutant protein failed to reach the plasma membrane,
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whereas the fully glycosylated form of wild type CFTR was
expressed on the cell surface (Fig. 3). 
To investigate the intracellular localizations of the mutant
CFTR, immunostaining was performed in HEK 293 cells
transfected with plasmids for wild type CFTR or CFTR car-
rying the L441P mutation. The CFTR protein was stained
with anti-CFTR 24-1 antibodies (R&D Systems, Minneapo-
lis, MN, USA) and fluorescein isothiocyante-conjugated sec-
ondary antibodies. The ER-resident calnexin protein was
stained with anti-calnexin antibodies (Abcam, Cambridge,
MA, USA) and rhodamine-conjugated secondary antibod-
ies, and then images were obtained with a Zeiss LSM510 con-
focal microscope. As shown in Fig. 4, wild type CFTR was
mainly localized on the plasma membrane (arrow heads). On
the other hand, L441P mutant protein was found in the ER,
which was confirmed by co-localization with calnexin, an ER
membrane protein (Fig. 4). 
It is well known that CFTR protein has a cAMP-activated
Cl- channel function (2). Thus, the cAMP-activated chloride
channel activities of CFTR-expressing HEK 293 cells were
measured in the whole cell configuration. Treatments with
the adenylyl cyclase activator forskolin (FSK) produced a large
inward current in NMDG-Cl solutions (Fig. 5). The I-V rela-
tionship measurements revealed the typical CFTR current
of a linear I-V relationship when a ramp pulse from -120 mV
to+120 mV was applied at peak current (Fig. 5B). The cur-
rent density of wild type CFTR at a -30 mV holding poten-
tial was 37.48±6.20 pA/pF. However, the cAMP treatment
(5 μM FSK) failed to activate the Cl- currents in cells trans-
fected with L441P mutant CFTR (Fig. 5).
DISCUSSION
CF is caused by the loss-of-function mutations in the CFTR
gene and inherited as an autosomal recessive trait. The clas-
sical form of CF is characterized by the progressive lung dis-
ease, pancreatic dysfunction, elevated sweat electrolytes, and
male infertility (12). However, a wide variability in the clini-
cal presentation is found among patients. For example, only
about 20% of affected infants are born with intestinal obstruc-
tion and meconium ileus. Other patients are diagnosed with
various modes of presentation from birth to adulthood and
with considerable variability in the severity and rate of dis-
Fig. 4. Immunocytochemistry of L441P mutant CFTR. HEK 293 cells were transfected with plasmids for wild type CFTR or CFTR carrying
the L441P mutation, immunostained with anti-CFTR 24-1 antibody (R&D Systems) and fluorescein isothiocyante-conjugated secondary
antibodies. The calnexin protein was stained with anti-calexin antibodies (Abcam) and rhodamine-conjugated secondary antibodies.
Images were collected with a Zeiss LSM510 confocal microscope.
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ease progression. Although progressive lung disease is the
most common cause of mortality in CF, there is great vari-
ability in the age of onset and severity of lung disease in dif-
ferent age groups. Effects from other genes and environmen-
tal factors are suggested to make important contributions to
disease progression, because pulmonary phenotype varies even
within the same CFTR mutations (5). The non-classic or vari-
ant form of CF presents clinical diseases in only a single or
subgroup of organs, such as monosymptomatic brochiecta-
sis, chronic pancreatitis, or congenital absence of vas deferens.
In general, it is believed that complete loss of CFTR func-
tion by the biallelic severe mutations is associated with the
classical form, and the reduced CFTR function by mild muta-
tions is associated with the variant form of CF.
Our patient had the classical form of CF presenting both
respiratory and gastrointestinal diseases. The chest and ab-
dominal CT scans revealed the bronchiectasis in both lung
fields and atrophy of the pancreas, respectively. The patient
has suffered from recurrent pneumonia and chronic diarrhea
since her infancy. At this admission, her sputum specimens
were positive to P. aeruginosa, the most commonly identified
pathogen from the respiratory tract cultures of CF patients
(13). Finally, CF was confirmed by the positive sweat chlo-
ride test. 
Currently, over 1,000 mutations and 200 polymorphic loci
in the CFTR gene have now been identified (http://www.
genet.sickkids.on.ca/cftr/). It is almost impossible to exam-
ine all these loci for the clinical diagnosis of CF. Alternative-
ly, genetic tests on the 20 most common loci have been ob-
served that can cover approximately 80-90% of mutations
in Caucasian population (Elucigen CF20 Kit, Zeneca Diag-
nostics, Oxfordshire UK). Therefore, genetic analysis is a use-
ful diagnostic tool when information on the prevalent muta-
tions in the population is available, because identification of
the CFTR mutation is highly specific evidence of cystic fibro-
sis. Unfortunately, the CFTR mutation spectrum in the Kore-
an population has not been fully determined yet. 
Previously we have identified the 11 CFTR mutations and
polymorphisms circulating in the Korean population (10).
Some of them, especially E117G and Q1352H, showed an
association with the monosymptomatic bronchiectasis or
chronic pancreatitis. Furthermore, molecular study on these
mutants showed a reduced Cl- channel activity (10). How-
ever, none of the above mutations were identified in the pa-
tient’s gene of this study. A thorough examination on the
coding regions and exon-intron splicing junctions revealed
the L441P non-synonymous mutation in one allele. How-
ever, mutations in the second allele were not observed. Two
explanations are possible. First, the disease causing mutation
may exist in the deep intronic regions or may associate with
mechanisms not explored in this study, such as gross dele-
tions, complex rearrangements and repeat variations (http:
//www.hgmd.cf.ac.uk/ac/index.php). In general, most of dis-
ease-causing mutations are located on the coding regions and
exon-intron splicing junctions where mutations can easily
affect the structure and function of the gene product. How-
ever, in some cases, mutations in the deep intronic regions
also can ablate the gene functions for variable reasons. For
example, deep intronic mutations of 1,811+1.6 kbA>G at
intron 11 and 3,600+11.5 kbC>G at intron 18 have been
shown to be associated with CF in Spanish and African pati-
ents, respectively (14, 15). Second, it has been shown that
significant proportions of CF patients have only one or no
CFTR mutations even after an intensive genetic search (16).
Therefore, the defects in other gene may compensate CFTR
functions. Especially in the case of variant CF, the defects or
environmental factors may contribute to the pathogenesis of
CFTR even without second allele mutation in the CFTR gene.
Fig. 5. cAMP-activated Cl- channel activity of L441P mutant CFTR. HEK 293 cells were transfected with plasmids for wild type CFTR or CFTR
carrying the L441P mutation and the cAMP-activated Cl- channel activity was measured in the whole cell configuration. (A) Cells were stimu-
lated with forskolin (5 μM) and the currents were measured at a -30 mV holding potential. Mean currents were normalized as current den-
sities (pA/pF, n=6 for wild type CFTR and n=10 for L441P mutant CFTR). (B) The I-V relationships were obtained with a step pulse from -
120 mV to+120 mV applied at peak current.
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Defects in the protein folding and processing during the
secretory pathway of membrane protein are the major molec-
ular pathogenic mechanisms of mutant CFTR (4). This causes
an aberrant Cl- and HCO3- transport in the respiratory and
pancreatic epithelia (17). The present study is the first study
that substantially demonstrated the pathogenicity of the
L441P mutation. An integrated molecular physiologic exam-
ination revealed that the L441P mutation causes a process-
ing defect. The L441P mutant protein was not fully glyco-
sylated, which implies that the L441P mutant protein can
not travel to the Golgi-complex and subsequently to the
membrane. This was verified by the absence of L441P mutant
protein in the plasma membrane in immunostatining and
surface biotinylation experiments. Consequently, the cAMP-
activated chloride channel activities of CFTR were complete-
ly deteriorated by the L441P mutation. 
CF is not common in Asians and there are only a few re-
ports of CF in Korea (6-9). However, analysis of the CFTR
haplotype structure revealed that significant proportions of
Koreans have minor CFTR mutants, although the major
disease causing alleles, such as DF508 and G551D, are ext-
remely rare (10). The heterozygote frequency of mild muta-
tions, such as E217G and Q1352H, was estimated to 0.5-
1% in the Korean population. This suggests that the inci-
dence of classical and variant CF would be around 1 in 10,000
to 40,000 live births. Although CF is relatively rare in the
Korean population, CF should be considered in patients with
recurrent chronic respiratory symptoms. 
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